NASDAQ:TNGX Tango Therapeutics Q2 2026 Earnings Results & Report $23.81 +1.24 (+5.49%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$23.80 -0.01 (-0.05%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tango Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.37 versus the -$0.3172 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 11, 2026TimeBefore Market OpensConference Call7:00 AM ET Tango Therapeutics EPS ResultsActual EPS-$0.37Consensus EPS -$0.3172Beat/MissMissed by -$0.0528One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersTango Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.56 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTango Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tango Therapeutics Q2 2026 Earnings FAQ Did Tango Therapeutics beat earnings estimates for Q2 2026? Tango Therapeutics (NASDAQ:TNGX) reported earnings of -$0.37 per share for Q2 2026, missing the consensus estimate of -$0.3172. The report was announced on Tuesday, August 11, 2026. When is Tango Therapeutics' next earnings date? Tango Therapeutics' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Tango Therapeutics on the company's earnings history page. Tango Therapeutics Earnings HeadlinesComparing Alumis (NASDAQ:ALMS) & Tango Therapeutics (NASDAQ:TNGX)October 8 at 5:58 AM | americanbankingnews.comTango Therapeutics Insider Sold Shares Worth $660,796, According to a Recent SEC FilingOctober 6, 2026 | marketscreener.comMThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan. | Base Camp Trading (Ad)Head-To-Head Analysis: GeoVax Labs (NASDAQ:GOVX) versus Tango Therapeutics (NASDAQ:TNGX)September 30, 2026 | americanbankingnews.comTango Therapeutics, Inc. (TNGX)September 27, 2026 | finance.yahoo.comIl principale responsabile contabile di Tango Therapeutics vende azioni per $198kSeptember 25, 2026 | it.investing.comSee More Tango Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email. Email Address About Tango TherapeuticsTango Therapeutics (NASDAQ:TNGX) is a clinical-stage biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities and activate the immune system against tumors. The company uses functional genomics, including CRISPR-based screening, to identify genetic dependencies that may be selectively targeted in cancer cells while limiting effects on healthy tissue. Tango’s research and development programs include small-molecule therapies and immuno-oncology candidates designed to address genetically defined cancers. Its pipeline has included programs targeting MAT2A and other cancer-related pathways, as well as approaches intended to enhance the ability of T cells to recognize and destroy tumor cells. Headquartered in Boston, Massachusetts, Tango Therapeutics was founded in 2017 and has collaborated with Gilead Sciences on the discovery and development of cancer immunotherapies. The company is led by President and Chief Executive Officer Barbara Weber, M.D., and primarily serves the global biopharmaceutical and oncology markets through its research, clinical development and strategic partnerships.View Tango Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
